Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: Correlation with clinicopathological features and prognosis

Journal of Oral Pathology and Medicine

Volumn 40, Issue 9, 2011, Pages 693-698

  Kato, Koroku ^a   Kawashiri, Shuichi ^a   Yoshizawa, Kunio ^a   Kitahara, Hiroko ^a   Okamune, Ayako ^a   Sugiura, Shirou ^a   Noguchi, Natsuyo ^a   Yamamoto, Etsuhide ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Invasive front; Oral squamous cell carcinoma; P53; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL NUCLEUS; COLORING AGENTS; FEMALE; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; GINGIVAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL RATE; TONGUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053526676     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01032.x     Document Type: Article

References (34)

1. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-7.
2. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71: 543-6.
3. Iggo R, Gatter K, Bartek J, Lane D, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
4. Osborne RJ, Merlo GR, Mitsudomi T, et al. Mutations in the p53 gene in primary human breast cancers. Cancer Res 1991; 51: 6194-8.
5. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol 1991; 138: 807-13.
6. Holm R, Skomedal H, Helland Å, Kristensen G, Børresen A, Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 1993; 169: 21-6.
7. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early noninvasive lesions. Oncogene 1995; 10: 1217-27.
8. Raybaud-Diogene H, Tetu B, Morency R, Fortin A, Monteil RA. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 1996; 32B: 143-9.
9. Regezi JA, Varbo RJ, Regev E, Pisanty S, Silverman S, Gazit D. p53 expression in sequential oral dysplasia and in situ carcinomas. J Oral Pathol Med 1995; 24: 18-22.
10. Cruz IB, Meijer CJ, Snijders PJ, Snow GB, Walboomers JM, van Der Waal I. p53 immunoexpression in non-malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management. J pathol 2001; 191: 132-7.
11. Stoimenov I, Helleday T. PCNA in the crossroad of cancer. Biochem Soc Trans 2009; 37: 605-13.
12. Staibano S, Mignogna MD, Lo Muzio L, et al. Overexpression of cyclin-D1, bcl-2, and bax proteins, proliferating cell nuclear antigen (PCNA), and DNA-ploidy in squamous cell carcinoma of the oralcavity. Hum Pathol 1998; 29: 1189-94.
13. Franchi A, Gallo O, Boddi V, Santucci M. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination. Clin Cancer Res 1996; 2: 1801-8.
14. Lee JJ, Kuo MY, Cheng SJ, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 471-8.
15. Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of oral cavity. Head Neck Surg 1984; 6: 939-47.
16. Beenken SW, Krontiras H, Maddox WA, Peters GE, Soong S, Urist MM. T1 and T2 squamous cell carcinoma of the oral tongue: prognostic factors and the role of elective lymph node dissection. Head Neck 1999; 21: 124-30.
17. Bryne M. Is the invasive front of an oral carcinoma the most important area for prognostication? Oral Dis 1998; 4: 70-7.
18. Bankfalvi A, Piffko J. Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med 2000; 29: 291-8.
19. Piffko J, Bankfalvi A, Tory K, et al. Molecular assessment of p53 abnormalities at the invasive front of oral squamous cell carcinoma. Head Neck 1998; 20: 8-15.
20. Osaki T, Kimura T, Tatemoto Y, Yamamoto T, Yoneda K. Risk factors of metastasis in oral squamous cell carcinomas. Oncology 2000; 58: 137-43.
21. Leedy DA, Trune DR, Kronz JD, Weidner N, Cohen JI. Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg 1994; 111: 417-22.
22. Kato K, Kawashiri S, Tanaka A, et al. Predictive value of measuring p53 labeling index at the invasive front of oral squamous cell carcinomas. Pathol Oncol Res 2008; 14: 57-61.
23. Qin LF, Ng IO, Fan ST, Ng M. p21/WAF1, p53and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998; 79: 424-8.
24. Waga S, Honnon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-8.
25. Tsuji T, Mimura Y, Wen S, et al. The significance of PCNA and p53 protein in some oral tumours. Int J Oral Maxillifac Surg 1995; 24: 221-5.
26. Aoyagi K, Kohfuji K, Yano S, et al. The expression of proliferating cell nuclear antigen, p53, p21, and apoptosis in primary gastric lymphoma. Surgery 2002; 132: 20-6.
27. Bartkova J, Grøn B, Dabelsteen E, Bartek J. Cell-cycle regulatory proteins in human wound healing. Arch Oral Biol 2003; 48: 125-32.
28. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 2006; 53: 799-808.
29. Keum KC, Chung EJ, Koom WS, et al. Predictive value of p53 and PCNA expression for occult neck metastases in patients with clinically node-negative oral tongue cancer. Otolaryngol Head Neck Surg 2006; 135: 858-64.
30. Sidari L, Tirelli G, Papanikolla L, Sasso F, Russolo M, Melato M. Flow cytometry expression of p53 and PCNA in oral/oropharynx carcinomas and their lymph node metastases. Anticancer Res 2003; 23: 4127-32.
31. de Sousa FA, Paradella TC, Carvalho YR, Rosa LE. Comparative analysis of the expression of proliferating cell nuclear antigen, p53, bax, and bcl-2 in oral lichen planus and oral squamous cell carcinoma. Ann Diagn Pathol 2009; 13: 308-12.
32. Sittel C, Ruiz S, Volling P, Kvasnicka HM, Jungehülsing M, Eckel HE. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol 1999; 35: 583-9.
33. Yamamoto E, Sunakawa H, Kohama G. Clinical course of diffuse invasive carcinoma of the tongue excised after Bleomycin treatment. J Maxillofac Surg 1983; 11: 269-74.
34. Dworakowska D, Jassem E, Jassem J, et al. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer. Lung Cancer 2009; 66: 127-33.